Global Gonorrhea Pipeline Review 2020: Therapeutic Analysis of 16 Companies and Drug Profiles – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Gonorrhea – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Gonorrhea – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Gonorrhea (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gonorrhea (Infectious Disease) pipeline guide also reviews the key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 4, 11, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Gonorrhea (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Gonorrhea (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Gonorrhea (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. (Read more…)
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Gonorrhea (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Gonorrhea (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Gonorrhea (Infectious Disease)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Gonorrhea (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Gonorrhea (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Topics Covered:

Introduction

• Gonorrhea – Overview
• Gonorrhea – Therapeutics Development

Gonorrhea – Therapeutics Assessment

Gonorrhea – Companies Involved in Therapeutics Development

• Gonorrhea – Drug Profiles

Gonorrhea – Dormant Projects

• Gonorrhea – Discontinued Products
• Gonorrhea – Product Development Milestones

Appendix

Companies Mentioned

• Biolytics Pharma
• Boulos and Cooper Pharmaceuticals Pty Ltd
• Debiopharm International SA
• Entasis Therapeutics Holdings Inc
• Evofem Biosciences Inc
• GlaxoSmithKline Plc
• Hsiri Therapeutics LLC
• Melinta Therapeutics Inc
• Merck & Co Inc
• Microbiotix Inc
• Nabriva Therapeutics Plc
• Paratek Pharmaceuticals Inc
• Pharmiva AB
• Redx Pharma Plc
• TherapyX Inc
• Yaso Therapeutics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/n032x1

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900